Realbotix Q3 2026 earnings: Robotics sales rise as total revenue falls

Realbotix (OTC: XBOTF; TSXV: XBOT) reported fiscal Q3 2026 revenue of $354,000, down 40.5% from $595,000 a year earlier, and a total comprehensive loss of $1.695 million versus income of $12,000. For the quarter ended June 30, 2026, emerging robotics revenue was not enough to offset lower Intima sales, contracting gross margin, and higher investment in staff and manufacturing capacity.

Core financial results

The revenue decline primarily reflected Realbotix’s planned repositioning of Intima LLC and the unusually high comparison created by fulfillment of historical Intima orders in the prior-year period. Revenue was also affected by the disposal of crypto-staking operations, the wind-down of other crypto activities, and the streamlining of legacy products.

Profitability weakened as early robotic deployments carried manufacturing scale-up costs and less favorable initial economics. A one-time accounting adjustment that moved overhead expenses into cost of sales also reduced the reported gross margin.

For the nine months ended June 30, 2026, revenue was $932,000 versus $2.138 million a year earlier. The nine-month comprehensive loss narrowed to $2.544 million from $3.928 million, helped by one-time gains from debt repayment and the sale of the Tokens.com domain, as well as the absence of further crypto-asset revaluation effects.

Business and segment performance

The revenue mix shifted materially toward Realbotix LLC, although Intima remained the larger contributor. Realbotix LLC generated revenue from completed robot deliveries and event-related support services, while Intima’s comparison was affected by prior-year backlog fulfillment.

Realbotix LLC accounted for approximately 37% of consolidated quarterly revenue, compared with its historical contribution of less than 5%. Management cited deployments involving a large telecommunications enterprise, senior residences, education, and a television program, but did not disclose revenue associated with individual projects.

Intima’s current revenue was described as more representative of ongoing demand after the prior-year backlog was fulfilled. The subsidiary continued its commercial repositioning through product preparations, ecommerce modernization, manufacturing-system upgrades, and the beta launch of Xmode, an embodied-AI platform connecting conversational AI with physical products.

Profitability and cost structure

At a 24.4% gross margin, quarterly revenue implies gross profit of approximately $86,000. That amount was substantially below operating expenses of $1.821 million, illustrating the financial gap between the company’s current commercial scale and its investment program.

Operating expenses increased by approximately 38% as Realbotix expanded hiring for humanoid robotics and AI products and built additional manufacturing capacity. Realbotix LLC’s robotics, AI, and engineering team grew from eight employees in the prior-year period to more than 20 full-time equivalents.

The comprehensive loss occurred despite the benefit of one-time gains. This indicates that lower gross profit and the expanding operating cost base remained the dominant factors in the quarterly result.

Management’s strategy

Management is moving Realbotix LLC from customized demonstrations toward products designed for broader deployment. The company plans to unveil a new robot line, tentatively called Echo Generation One, in 2026 using a direct-to-buyer, online-only sales model. The design and pricing strategy are intended to support more affordable and easier-to-manufacture products as production scales in 2027.

Realbotix LLC also plans to introduce situational AI avatar products as an entry point into its robot lineup. At Intima, management said feedback from the Xmode beta supports a strategy focused on providing hardware infrastructure that connects third-party AI platforms with physical experiences, rather than developing another standalone AI companion application.

The company also expects its previously announced all-share reverse takeover transaction with Onconetix (Nasdaq: ONCO) to close in the fourth quarter of 2026. The transaction is intended to list Realbotix LLC on the Nasdaq Capital Market, with Realbotix retaining majority ownership through the ONCO common shares it receives.

Risks investors need to watch

• Early deployment economics: Manufacturing scale-up costs and initial robot deployments contributed to the 12.7-percentage-point gross-margin contraction. The timing and economics of moving from customized projects to standardized production remain important.
• Intima’s lower revenue base: Intima revenue fell 62.7% after the prior-year backlog was fulfilled. Rebuilding market share and converting upcoming product launches into recurring demand will affect consolidated revenue.
• Expenses are rising ahead of scale: Operating expenses grew 38.2% as the company expanded its team and manufacturing capacity, while quarterly revenue declined. Continued investment without sufficient commercial volume could prolong losses.
• Product launch and production execution: Echo Generation One remains planned rather than launched, and larger-scale production is targeted for 2027. Results will depend on completing product development and establishing a workable direct-sales and manufacturing model.
• Reverse takeover completion: The proposed Onconetix transaction is expected to close in Q4 2026, but it remains pending. Any delay or change could affect the planned Nasdaq listing of Realbotix LLC.

Summary

Realbotix’s Q3 2026 results show an early shift in revenue toward humanoid robotics, but that transition has not yet compensated for Intima’s lower sales or the cost of expanding robotics operations. The next operating milestones are whether robot deployments develop into scalable revenue, whether gross margin recovers as manufacturing matures, and whether planned product launches and the Onconetix transaction proceed on schedule.